Recent Updates
Recently added Catalysts
ETON Positive Sentiment Score: 70/100

Eton Pharmaceuticals to Report Fourth Quarter and Full Year 2023 Financial Results on Thursday, March 14, 2024

Thursday, February 29, 2024 2 min read
Key Takeaway: Eton Pharmaceuticals, a company focused on developing treatments for rare diseases, will report its fourth quarter and full year 2023 financial results on March 14, 2024. Following the announcement, management will host a conference call and live audio webcast at 4:30 p.m. ET to discuss the results with investors. The company currently has several FDA-approved products and is advancing additional product candidates in development.

Market Sentiment Analysis

POSITIVE FACTORS

  • Eton Pharmaceuticals has scheduled a conference call to discuss its financial results.
  • The company has four FDA-approved rare disease products, showcasing its innovation.
  • Eton is actively developing additional product candidates in late-stage development.

Full Press Release Details

DEER PARK, Ill., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (“Eton” or the "Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that it will report fourth quarter and full year 2023 financial results on Thursday, March 14, 2024. Management will host a conference call and live audio webcast to discuss these results at 4:30 p.m. ET (3:30 p.m. CT).
Register* (Audio Only) Click here
In addition to taking live questions from participants on the conference call, management will be answering emailed questions from investors. Investors can email questions to: investorrelations@etonpharma.com.
The live webcast can be accessed on the Investors section of Eton’s website at https://ir.etonpharma.com/. An archived webcast will be available on Eton’s website approximately two hours after the completion of the event and for 30 days thereafter.
* Conference call participants should register to obtain their dial-in and passcode details. Please be sure to register using a valid email address.
About Eton Pharmaceuticals
Eton is an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases. The Company currently has four FDA-approved rare disease products: ALKINDI SPRINKLE®, Carglumic Acid, Betaine Anhydrous, and Nitisinone. The Company has three additional product candidates in late-stage development: ET-400, ET-600, and ZENEO® hydrocortisone autoinjector. For more information, please visit our website at www.etonpharma.com.
Lisa M. Wilson, In-Site Communications, Inc.
E: lwilson@insitecony.com
Source: Eton Pharmaceuticals

Frequently Asked Questions

When will Eton Pharmaceuticals report its financial results?

Eton Pharmaceuticals will report their financial results on March 14, 2024.

How can I access the live webcast for Eton's financial results?

The live webcast can be accessed via Eton's Investors section on their website.

Can investors ask questions during the conference call?

Yes, investors can ask live questions or email them to Eton's investor relations.

What products does Eton Pharmaceuticals have approved?

Eton has four FDA-approved products for rare diseases, including ALKINDI SPRINKLE®.

What are Eton's upcoming product candidates?

Eton has three late-stage product candidates: ET-400, ET-600, and ZENEO® autoinjector.

Tags: ETON Viatris Investor Conferences Healthcare Eton Pharmaceuticals financial results rare diseases FDA-approved products
Last updated: Feb 29, 2024